Amgen Inc. (AMGN) is a Drug Manufacturers - General company in the Healthcare sector, currently trading at $350.95. It has a SharesGrow Score of 64/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of AMGN = $457.46 (+30.3% from the current price, the stock appears undervalued). Analyst consensus target is AMGN = $348 (-0.9% upside).
Valuation: AMGN trades at a trailing Price-to-Earnings (P/E) of 24.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 5.87.
Financials: revenue is $36.7B, +11.9%/yr average growth. Net income is $7.7B, growing at +17.3%/yr. Net profit margin is 21% (strong). Gross margin is 70.8% (-4.9 pp trend).
Balance sheet: total debt is $54.6B against $8.7B equity (Debt-to-Equity (D/E) ratio 6.31, leveraged). Current ratio is 1.14 (adequate). Debt-to-assets is 60.3%. Total assets: $90.6B.
Analyst outlook: 22 / 38 analysts rate AMGN as buy (58%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 33/100 (Fail), Growth 80/100 (Pass), Past 100/100 (Pass), Health 33/100 (Fail), Moat 81/100 (Pass), Future 38/100 (Fail), Income 85/100 (Pass).
